Biotech Acquisition Company Class A (BIOT)

Name: Biotech Acquisition Company Class A (BIOT) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Biotech Acquisition Company Class A (BIOT)

Stock Card

$10.15

$0.00 (0.00%)

As on 10-Feb-2023 09:30EDT

Market cap

$292 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

1.3

Div. Yield

0 %

Biotechcquisition Company Class A (BIOT) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 10.15 High: 10.15

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$8 Mln
ROE

0 %
ROCE

-- %
Industry P/E

25.82
EV/EBITDA

-77.6
Debt to Equity

0
Book Value

$--
EPS

$1.3
Face value

--
Shares outstanding

23,000,000

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Biotechcquisition Company Class A (BIOT)	0.5	0.1	1.5	2.9	--	--	--
BSE Sensex^*	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4

As on 10-Feb-2023 | *As on 04-Sep-2026

The underlying data is unavailable.

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Biotechcquisition Company Class A (BIOT)	10.2	291.8	0.0	8.0	--	--	39	1.3
Barrett Business Services (BBSI)	33.9	833.0	1,266.4	35.1	4.8	15.8	25.5	4.1
Insperity (NSP)	51.6	1,979.3	6,872.0	-16.0	0.1	-29.9	--	32.2
Kelly Services A Inc (KELYA)	16.7	600.2	4,063.1	-273.4	-2.5	-27.9	--	0.6
Kelly Services B Inc (KELYB)	23.3	808.2	4,063.1	-273.4	-2.5	-27.9	--	0.8
Kforce (KFRC)	53.6	976.6	1,344.4	36.5	3.9	29.4	25.7	7.8
Korn Ferry (KFY)	85.6	4,383.3	2,938.6	277.4	13.9	14.5	16.4	2.2
ManpowerGroup (MAN)	61.7	2,882.5	18,718.1	104.2	1.9	5	27.7	1.3
TriNet Group (TNET)	68.4	3,186.7	4,884.0	175.0	6.2	195.5	18.4	24.6
Upwork (UPWK)	8.8	1,126.6	787.3	101.8	17.8	16.4	11.4	1.8

Shareholding Pattern

View Details

About Biotechcquisition Company Class A (BIOT)

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was... incorporated in 2020 and is based in New York, New York. Read more

Chairman & CEO

Dr. Michael Shleifer Ph.D.
Chairman & CEO

Dr. Michael Shleifer Ph.D.
Headquarters

New York, NY
Website

--

FAQs for Biotechcquisition Company Class A (BIOT)

What is the current share price of Biotech Acquisition Company Class A (BIOT) Today?

The share price of Biotech Acquisition Company Class A (BIOT) is $10.15 (NASDAQ) as of 10-Feb-2023 09:30 EDT. Biotech Acquisition Company Class A (BIOT) has given a return of 2.94% in the last 1 years.

What is the current PB & PE ratio of Biotech Acquisition Company Class A (BIOT)?

The P/E ratio of Biotech Acquisition Company Class A (BIOT) is 39.04 times as on 10-Feb-2023, a 51 premium to its peers’ median range of 25.82 times.
The P/B ratio of Biotech Acquisition Company Class A (BIOT) is 1.33 times as on 10-Feb-2023, a 84 discount to its peers’ median range of 8.39 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2021	-8.59	-2,184,444.44
2020	--	--
2021	-8.59	-2,184,444.44
2020	--	--

What is the 52 Week High and Low of Biotech Acquisition Company Class A (BIOT)?

The 52-week high and low of Biotech Acquisition Company Class A (BIOT) are Rs -- and Rs -- as of 05-Sep-2026.

What is the market cap of Biotech Acquisition Company Class A (BIOT)?

Biotech Acquisition Company Class A (BIOT) has a market capitalisation of $ 292 Mln as on 10-Feb-2023. As per SEBI classification, it is a company.

Should I invest in Biotech Acquisition Company Class A (BIOT)?

Before investing in Biotech Acquisition Company Class A (BIOT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.